about
RNAIII-inhibiting peptide affects biofilm formation in a rat model of staphylococcal ureteral stent infectionRecent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer.D2-40 immunoreactivity in penile squamous cell carcinoma: a marker of aggressiveness.Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma.Green fluorescent protein as indicator of nonviral transient transfection efficiency in endometrial and testicular biopsies.Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens.Tolerability of prostate transrectal biopsies using gel and local anesthetics: results of a randomized clinical trial.BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection.The antimicrobial peptide tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model.Nebivolol induces, via β3 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes.α1-Blockers for the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a prospective randomized study.The role of uroflowmetry biofeedback and biofeedback training of the pelvic floor muscles in the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a randomized controlled prospective study.Nitric oxide synthase expression in rat anorectal tissue after sacral neuromodulation.Perineal ultrasound evaluation of dysfunctional voiding in women with recurrent urinary tract infections.Correlation between urodynamics and perineal ultrasound in female patients with urinary incontinence.Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients.Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans.Efficacy of Tigecycline and Rifampin Alone and in Combination against Enterococcus faecalis Biofilm Infection in a Rat Model of Ureteral StentEffect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infectionPrognostic value of CD44 expression in penile squamous cell carcinoma: a pilot studySacral neuromodulation in patients with multiple sclerosisAngiotensinogen promoter variants influence gene expression in human kidney and visceral adipose tissueVEGF, survivin and NOS overexpression in psoriatic skin: Critical role of nitric oxide synthasesPROGNOSTIC ROLE OF FUHRMAN GRADE AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN pT1a CLEAR CELL CARCINOMA IN PARTIAL NEPHRECTOMY SPECIMENSSAFETY AND EFFICACY OF TRANSURETHRAL RESECTION OF PROSTATE GLANDS UP TO 150 ML: A PROSPECTIVE COMPARATIVE STUDY WITH 1 YEAR OF FOLLOWUPProduction of Serum-free and Total Prostate-specific Antigen Due to Prostatic Intraepithelial NeoplasiaDiagnostic Accuracy of Percent Free Prostate-Specific Antigen in Prostatic Pathology and Its Usefulness in Monitoring Prostatic Cancer PatientsSerum markers for monitoring of prostatic carcinoma
P50
Q24682401-C2FA0BA6-185F-4918-A92D-07227DD5443BQ38334611-E2C7482E-ED4C-4D03-99FF-0B0A1B5C86B9Q40824744-CBB29EC2-EA1D-46DC-969D-13DB7DD562BDQ42486851-E79880FA-C431-4C25-8704-D7C414D7C7C4Q43739592-C27C9E0D-76B7-4806-8F91-836963129E1AQ45888702-BDCC6252-930C-4986-80EE-44B83122FDC8Q46407811-540B3905-882A-471C-9760-E9BEF745A054Q46625867-61C1277C-637D-41DA-8794-421CF8E0E794Q46631559-5DE6EB4B-1BEE-4FEA-BF37-EB472DF71389Q46894050-2B4D8276-F488-4704-9633-FB2AB24AD459Q47198817-1E08A05A-0F9B-4D76-B8DE-86750CC51446Q48067628-BF7CC26B-4964-4A64-B065-9F203707A681Q48858066-FAC70F2E-23DC-4A55-B79D-8BEEBC0A563BQ51421776-C4B129AF-1DDD-44A0-9500-81D1EB03DB3AQ51718733-A7125E65-9467-4BB5-88A3-4BB20E505F05Q51782692-C1DD315E-D3D4-406A-9DA9-1741D4E5619AQ51821415-F56F5ED0-FCC3-4DF1-8BB2-5AB94DF6F79DQ53324091-61D32194-0372-4B63-8DEB-FA3226D00E5DQ59420835-C53CADA3-FB79-4713-BD58-E1EA3C630EC2Q59420848-A67228B9-18AC-4F18-B921-BF0C7D29980CQ60704840-15290393-E473-4B99-B71F-109CC6BF9C40Q60704843-F913E894-9B06-470C-BDCA-75502A8B9C5FQ60704850-736541DB-6352-4672-AB64-CCFA46E39EA7Q60704861-8B49D233-81EF-4F7F-B874-39B416AE93FBQ60704885-92CF8F90-2767-444A-BB18-F75A054861CFQ60704903-CA6AF71B-E784-4C39-9DC1-B73F1824DBC1Q60704912-ADDE8238-FE34-4FF4-88AB-85C522D4BBB8Q60704916-6A412E05-C26C-42A7-8214-005362B2C3BBQ73868533-F40B6BD4-567E-4137-9DC1-F0BC50E8A523
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Daniele Minardi
@ast
Daniele Minardi
@en
Daniele Minardi
@es
Daniele Minardi
@nl
Daniele Minardi
@sl
type
label
Daniele Minardi
@ast
Daniele Minardi
@en
Daniele Minardi
@es
Daniele Minardi
@nl
Daniele Minardi
@sl
prefLabel
Daniele Minardi
@ast
Daniele Minardi
@en
Daniele Minardi
@es
Daniele Minardi
@nl
Daniele Minardi
@sl
P106
P1153
7004098368
P21
P31
P496
0000-0002-9141-4959